Showcases (previously named Product Theaters) provide time for presentation of new research findings, showcasing of product details, giving demonstrations, and highlighting new products. These sessions may be promotional or non-promotional but are not eligible for continuing education credits. 

Attendees! A few reminders:

• Your badge may be scanned upon entry capturing name, credentials, city, state only
• We appreciate you keeping noise to a minimum
• All events are live-streamed and recorded
• Fill the room front to back
• Do not sit at tables with reserved signs
• All industry events feature a meal or refreshment break served 15 minutes before the session start time in National A
• Meals are limited and will be served at tables only
• A limited number of vegetarian/vegan/gluten free meals are available. If desired, please inform the server upon taking a seat
• Plates will not be removed after programming starts to minimize noise

Monday, April 8, 6:15 AM - 7:15 AM (CDT)

Breakfast will be served from 7:00-7:15 AM Eastern outside National A, immediately before the program.

Learn More and Register

A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

Overview: Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on possible mechanisms for an innovative class of therapeutics that have shown promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.

Faculty

	José Rey, MS, PharmD, BCPP Professor of Pharmacy Practice Nova Southeastern University; Ft. Lauderdale, FL Clinical Psychopharmacologist South Florida State Hospital, Wellpath Recovery Solutions; Pembroke Pines, FL
Supported by Karuna, a Bristol Myers Squibb Company

Monday, April 8, 3:45 PM - 4:45 PM (CDT)

A refreshment break will be served from 4:30-4:45 PM Eastern in National A, immediately before the program.

Learn More and Register

Practical Learnings and Knowledge When Implementing Rapid TDM Blood Levels: A Focus on Clozapine and Beyond 

Overview: This workshop will discuss key concepts of when, and how, to use TDM and practical applications in specific clinical scenarios. It will cover how to practically apply therapeutic range recommendations in patient management, the role of norclozapine, how to integrate TDM with LAIs, and effective strategies for utilizing blood levels in clinical decision-making and treatment plan development. Join us for a comprehensive session that bridges theory with practical applications in the field.

Learning Objectives

1. Understand key concepts in TDM
2. Describe how to apply therapeutic range recommendations practically in patient management
3. Outline how to utilize blood levels for clinical decision-making and treatment plan development

Faculty

	Speaker: Georgios Schoretsanitis, MD, PhD Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich; Zurich, Switzerland Department of Psychiatry, The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks; New York, NY Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell; Hempstead, NY
	Moderator: Megan Ehret, PharmD, MS, BCPP Professor, Co-Director of Mental Health Program Department of Practice, Sciences, and Health Outcomes Research University of Maryland School of Pharmacy; Baltimore, MD
Supported by

Tuesday, April 9, 6:15 AM - 7:15 AM (CDT)

Breakfast will be served from 7:00-7:15 AM Eastern outside National A, immediately before the program.

Learn More and Register

UZEDY: An LAI With a Spectrum of Key Attributes for the Treatment of Schizophrenia

Overview: This presentation establishes what makes UZEDY different from other LAIs, including a review of distinguishing pharmacokinetic and administration related features. Key efficacy and safety are reviewed along with the once-monthly and once-every-two-month dosing options for UZEDY.

Learning Objectives

1. Understand the role of UZEDY as a long-acting injectable (LAI) treatment option for schizophrenia
2. Discuss the flexible once-monthly and once-every-2-months dosing options of UZEDY
3. Review the attributes of UZEDY, including initiation without loading dose or oral supplementation

Faculty

	Ilan Melnick, MD Chief Medical Officer, Passageway Adult Mental Health; Miami, FL   Medical Director, Jewish Community Services of South Florida - Mental Health Service; Miami, FL
Supported by